Tag: diabetes

1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of patients achieving HbA1c targets of less than 7.0%. 2. Compared to placebo, the proportion of adverse events with tirzepatide were mildly elevated. Evidence Rating Level: 1 (Excellent) Study Rundown: In many patients...
1. Time spent cycling was associated with lower all-cause and cardiovascular disease-specific mortality in this multicenter European cohort study of patients with diabetes, independent of other exercise. 2. Taking up cycling over a five-year period was associated with lower mortality rates compared with those who did not cycle at all. Evidence...
1. Widespread diabetes screening helps to identify asymptomatic patients with preserved renal function and low diabetes-associated cardiovascular risk. 2. New cardiovascular risk stratification strategies are needed given heterogeneous characteristics of patients with type 2 diabetes.  Evidence Rating Level: 2 (Good)  Study Rundown: In the last decade, New Zealand Ministry of Health has...
1. Time in range after 6 months was higher with rtCGM than with isCGM. 2. Participants on rtCGM scored better on the satisfaction subscale of the Diabetes Treatment Satisfaction Questionnaire status (mean difference of 2.34 points). Evidence Rating Level: 1 (Excellent) Study Rundown: Progress in the field of home glucose monitoring systems...
1. In Asian patients with type 2 diabetes, culturally contextualized smartphone-based application was effective in improving weight management and metabolic parameters within 6 months of use. 2. Patients randomized to include smartphone-based lifestyle interventions had a greater reduction in HbA1c levels and diabetes medications within 6 months of use. Evidence...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue...
1. Matched cohort meta-analysis showed significant morality and life expectancy benefits with metabolic–bariatric surgery compared to non-surgical management of obesity. 2. Survival benefits of bariatric surgery more apparent for individuals with type 2 diabetes.  Evidence Rating Level: 1 (Excellent) Study Rundown: Metabolic syndrome has been associated with significant morbidity and mortality, increasing...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like...
1. Intraoperative dexamethasone was shown to be non-inferior to placebo for surgical-site infection incidence. 2. Intraoperative dexamethasone was shown to lower postoperative nausea and vomiting 24 hours after the surgery. Evidence Rating Level: 1 (Excellent) Study Rundown: Dexamethasone prevents postoperative nausea and vomiting; however, there are concerns regarding the increased risk of...